Hampton Likely To Have Difficult Start As GSK Chairman
This article was originally published in The Tan Sheet
Executive Summary
Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring in the previously announced asset swap with Novartis, and increasing generic competition to its leading products.